HedgeChatter

  • Home /
  • Tag Archives

EPZM

Epizyme, Inc. to Report First Quarter Financial Results and Provide Corporate Update on May 13, 2014

[PR Newswire] – CAMBRIDGE, Mass., May 7, 2014 /PRNewswire/ — Epizyme, Inc. (EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host moreView todays social media effects on EPZMView the latest stocks trending across Twitter. Click to view dashboardSee who Epizyme is hiring next, click here to […]

May 7, 2014 Bystocknews , Comments Off on Epizyme, Inc. to Report First Quarter Financial Results and Provide Corporate Update on May 13, 2014 read more

Epizyme Initiates Pediatric MLL-r Proof-of-Concept Study for EPZ-5676

[PR Newswire] – CAMBRIDGE, Mass., May 7, 2014 /PRNewswire/ — Epizyme, Inc. (EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the initiation of moreView todays social media effects on EPZMView the latest stocks trending across Twitter. Click to view dashboardSee who Epizyme is hiring next, click here to view […]

May 7, 2014 Bystocknews , Comments Off on Epizyme Initiates Pediatric MLL-r Proof-of-Concept Study for EPZ-5676 read more

Epizyme, Inc. to Present at 34th Annual Cowen and Company Health Care Conference on March 3, 2014

[PR Newswire] – CAMBRIDGE, Mass., Feb. 28, 2014 /PRNewswire/ — Epizyme, Inc. (EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participatio moreView todays social media effects on EPZMView the latest stocks trending across Twitter. Click to view dashboardSee who Epizyme is hiring next, click here to view […]

February 28, 2014 Bystocknews , Comments Off on Epizyme, Inc. to Present at 34th Annual Cowen and Company Health Care Conference on March 3, 2014 read more

EPIZYME, INC. Files SEC form 10-K, Annual Report

moreView todays social media effects on EPZMView the latest stocks trending across Twitter. Click to view dashboardSee who Epizyme is hiring next, click here to view […]

February 28, 2014 Bystocknews , Comments Off on EPIZYME, INC. Files SEC form 10-K, Annual Report read more

4:27 pm Epizyme reports 2013 Collaboration revs of $68.5 mln and net loss of $3.5 mln; sees 2014 R&D expenses of approx. $75 mln and 2014 G&A expenses of approx. $20 mln

moreView todays social media effects on EPZMView the latest stocks trending across Twitter. Click to view dashboardSee who Epizyme is hiring next, click here to view […]

February 28, 2014 Bystocknews , Comments Off on 4:27 pm Epizyme reports 2013 Collaboration revs of $68.5 mln and net loss of $3.5 mln; sees 2014 R&D expenses of approx. $75 mln and 2014 G&A expenses of approx. $20 mln read more

4:27 pm Epizyme reports 2013 Collaboration revs of $68.5 mln and net loss of $3.5 mln; sees 2014 R&D expenses of approx. $75 mln and 2014 G&A expenses of approx. $20 mln

moreView todays social media effects on EPZMView the latest stocks trending across Twitter. Click to view dashboardSee who Epizyme is hiring next, click here to view […]

February 27, 2014 Bystocknews , Comments Off on 4:27 pm Epizyme reports 2013 Collaboration revs of $68.5 mln and net loss of $3.5 mln; sees 2014 R&D expenses of approx. $75 mln and 2014 G&A expenses of approx. $20 mln read more

Epizyme Announces 2013 Operating and Financial Results and Provides 2014 Guidance

[PR Newswire] – CAMBRIDGE, Mass., Feb. 27, 2014 /PRNewswire/ — Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined … moreView todays social media effects on EPZMView the latest stocks trending across Twitter. Click to view dashboardSee who Epizyme is hiring next, click here to view […]

February 27, 2014 Bystocknews , Comments Off on Epizyme Announces 2013 Operating and Financial Results and Provides 2014 Guidance read more